We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Missing Molecule Triggers Ovary Tumors

By Biotechdaily staff writers
Posted on 29 Jun 2005
A missing receptor molecule has been found to be a key factor in the growth of human ovary tumors. More...


This unexpected connection has now been confirmed by researchers at the Medical University of Vienna (Austria), who published their findings in the June 15, 2005, issue of the journal Molecular Cancer Research. The team also found out the possible genetic reason why the receptor molecule, which is a significant factor in controlling cell growth, is missing.

Programmed cell death, known as apoptosis, brings about the controlled death of single cells, if this proves to be beneficial for the entire organism. If this self-protective mechanism does not function correctly, then the destructive cells can grow unchecked. The investigators have now been able to ascertain that programmed cell death does not function in the cells of specific tumors in the ovaries, not because the starting signal is missing, but because this signal cannot be received by the cell.

This discovery demonstrated that these cells are missing a receptor molecule called DR4. DR4 is responsible for receiving the signal molecule tumor necrosis factor-related apoptosis inducing ligand (TRIAL), which triggers apoptosis in these cells.

"To begin with it was not evident what was missing in the signal transmission. The signal or the receptor molecule? To answer this question, we examined 10 different ovarian cancer cell lines. In doing this we found out that 40% of these specimens contained none or only a few DR4 receptor molecules,” explained Prof. Krainer. It was confirmed in additional testing that these cells respond poorly to TRIAL. This confirms that the missing receptor and not the missing signal can considerably contribute to tumor growth.

Additional assessment validated why there was such a small proportion of receptors. "There can be two reasons for the loss of a receptor molecule like DR4. Firstly, the responsible gene could have been lost or damaged. Secondly, this gene could have been modified in a way which would prevent it from functioning,” stated Prof. Krainer. It proved to be precisely the latter. Prof. Krainer and his coworkers discovered that in 75% of the specimens containing only a few DR4 receptors, the responsible gene was altered. Some components of this gene were modified by attaching methyl groups. Methylation is a typical process in which cells silence genes, but in the affected tumor cells, it noticeably occurs at the wrong time.

To conclude their study, Prof. Krainer and his coworkers retested their results. Their findings were validated by evaluating 36 different tumor tissues taken directly from patients. In comparison, these cells signify the real causes of disease much better than cell cultures typically used for experimental research. It was determined that in 20% of the tissues studied, the gene responsible for DR4 was methylated to a higher extent and DR4 was missing.

This research provides insights for future treatment through the significant finding that the methylation of the gene for DR4 can contribute to the formation of tumor formation. These therapies could manipulate the faulty signal transfer system, DR4-TRAIL, to make cancer cells return to the originally programmed cell death.


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.